SEC Form 4 · accession 0001209191-17-038449
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan E Freeman
Director
Period of report
Jun 6, 2017
Accepted (ET)
Jun 7, 2017 · 9:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $0.5429 | Jun 6, 2017 | A | 3,500 | A | — | Jun 6, 2027 | Common stock | 3,500 | 3,500 | D |
Explanation of responses
- F1The stock option vests in equal quarterly installments over one year beginning on the first quarterly anniversary of the grant date.